Literature DB >> 1351955

Association of IgM with IgG ANCA in patients presenting with pulmonary hemorrhage.

V L Esnault1, B Soleimani, M T Keogan, A A Brownlee, D R Jayne, C M Lockwood.   

Abstract

ANCA are markers for systemic vasculitis such as Wegener's granulomatosis (WG) and microscopic polyarteritis (MPA) and are usually of the IgG isotype. However, IgM ANCA may rarely occur in isolation, and in these circumstances, we have found that they are associated clinically with a syndrome of pulmonary hemorrhage and systemic vasculitis. How frequently IgM ANCA may occur in conjunction with IgG has not previously been investigated. We report here a study of 24 consecutive patients with IgG ANCA-positive systemic vasculitis (14 WG, 10 MPA) in whom we determined whether IgM ANCA occurred in association with IgG ANCA, and if so, whether this had clinical importance. Eight patients were found to have IgM ANCA as well as IgG ANCA, and of these, seven presented with severe pulmonary hemorrhage. None of the IgM ANCA-negative patients presented with pulmonary hemorrhage. Although the occurrence of pulmonary hemorrhage in ANCA positive vasculitis was closely correlated with the presence of IgM ANCA, the antigen specificity of these IgM autoantibodies was variable, since both myeloperoxidase (4 patients), PR3 (3 patients), and an unknown ANCA antigen (1 patient) were found to be targets. We conclude that knowledge of ANCA isotype may have important clinical and therapeutic implications for the management of patients with systemic vasculitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1351955     DOI: 10.1038/ki.1992.194

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

1.  Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases.

Authors:  H Chikazawa; K Nishiya; A Matsumori; K Hashimoto
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

2.  Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies.

Authors:  M T Keogan; V L Esnault; A J Green; C M Lockwood; D L Brown
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

Review 3.  Pulmonary vasculitis.

Authors:  A Burns
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

4.  A comparison of the characteristics of circulating anti-myeloperoxidase autoantibodies in vasculitis with those in non-vasculitic conditions.

Authors:  I C Locke; B Leaker; G Cambridge
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

5.  IgM ANCA in healthy individuals and in patients with ANCA-associated vasculitis.

Authors:  L S Jeffs; C A Peh; A Nelson; P G Tan; E Davey; K Chappell; G B Perkins; P R Hurtado
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

6.  Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Authors:  J M Clain; A M Hummel; J H Stone; F C Fervenza; G S Hoffman; C G M Kallenberg; C A Langford; W J McCune; P A Merkel; P A Monach; P Seo; R F Spiera; E W St Clair; S R Ytterberg; U Specks
Journal:  Clin Exp Immunol       Date:  2017-02-07       Impact factor: 4.330

7.  Neutrophil and recombinant myeloperoxidase as antigens in ANCA positive systemic vasculitis.

Authors:  A K Short; C M Lockwood; A Bollen; N Moguilevsky
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

Review 8.  [Pulmonary renal syndrome].

Authors:  K De Groot; W L Gross; A Schnabel
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

9.  Antineutrophil cytoplasmic antibodies in Wegener's granulomatosis.

Authors:  S N Wong; V Shah; M J Dillon
Journal:  Arch Dis Child       Date:  1998-09       Impact factor: 3.791

10.  Antineutrophil cytoplasm antibodies (ANCA) of IgA isotype in adult Henoch-Schönlein purpura.

Authors:  N Ronda; V L Esnault; L Layward; V Sepe; A Allen; J Feehally; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.